View in EDS HTML Full Text PDF Full Text

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Saved in:
Bibliographic Details
Title: Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Authors: Sharmin, Sifat1 (AUTHOR), Lefort, Mathilde2,3 (AUTHOR), Andersen, Johanna Balslev4 (AUTHOR), Leray, Emmanuelle2,3 (AUTHOR), Horakova, Dana5 (AUTHOR), Havrdova, Eva Kubala5 (AUTHOR), Alroughani, Raed6 (AUTHOR), Izquierdo, Guillermo7 (AUTHOR), Ozakbas, Serkan8 (AUTHOR), Patti, Francesco9,10 (AUTHOR), Onofrj, Marco11 (AUTHOR), Lugaresi, Alessandra12,13 (AUTHOR), Terzi, Murat14 (AUTHOR), Grammond, Pierre15 (AUTHOR), Grand'Maison, Francois16 (AUTHOR), Yamout, Bassem17 (AUTHOR), Prat, Alexandre18 (AUTHOR), Girard, Marc18 (AUTHOR), Duquette, Pierre18 (AUTHOR), Boz, Cavit19 (AUTHOR)
Source: CNS Drugs. Nov2021, Vol. 35 Issue 11, p1217-1232.
Database: SPORTDiscus with Full Text
Full text is not displayed to guests.
Description
ISSN:11727047
DOI:10.1007/s40263-021-00860-7